Suggested remit - To appraise the clinical and cost effectiveness of guselkumab within its marketing authorisation for treating active psoriatic arthritis.
Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
 
Status Schedule affected by COVID-19
Process STA 2018
ID number 1658

Provisional Schedule

Committee meeting 11 February 2021

Project Team

Project lead Kate Moore

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Janssen-Cilag (guselkumab)
Others Department of Health and Social Care
  NHS England
  NHS Kernow CCG
  NHS West Kent CCG
  Welsh Government
Patient carer groups Arthritis Action
  Arthritis and Musculoskeletal Alliance
  Muslim Council of Britain
  National Rheumatoid Arthritis Society
  Psoriasis and Psoriatic Arthritis Alliance
  Psoriasis Association
  Psoriasis Help Organisation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Versus Arthritis
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  British Geriatrics Society
  British Institute of Musculoskeletal Medicine
  British Orthopaedic Association
  British Skin Foundation
  British Society for Rheumatology
  British Society of Rehabilitation Medicine
  Chartered Society for Physiotherapy
  Physiotherapy Pain Association
  Primary Care Dermatology Society
  Primary Care Rheumatology Society
  Rheumatoid Arthritis Surgical Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Abbvie (adalimumab)
  Accord Healthcare (methotrexate)
  Advanz Pharma (methotrexate)
  Amgen (adalimumab)
  Aspire Pharma (leflunomide)
  Biogen (adalimumab, etanercept, infliximab)
  Bristol-Myers Squibb (abatacept)
  Celgene (apremilast)
  Cipla (methotrexate)
  Cresent Pharma (sulfasalazine)
  Dexcel Pharma (ciclosporin)
  Eli Lilly and Company (ixekuzimab)
  Genesis Pharmaceuticals (sulfasalazine)
  Janssen-Cilag (ustekinumab)
  Medac (leflunomide, methotrexate)
  Merck Sharp & Dohme (golimumab, infliximab)
  Morningside Healthcare (leflunomide, methotrexate)
  Mylan (adalimumab, ciclosporin, leflunomide)
  Napp (infliximab)
  Nordic Pharma (methotrexate)
  Novartis Pharmaceuticals (ciclosporin, secukinumab)
  Orion Pharma (methotrexate)
  Pfizer (infliximab, etanercept, methotrexate, sulfasalazine, tofacitinib)
  Rosemont Pharmaceuticals (methotrexate, sulfasalazine)
  Sandoz (adalimumab, etanercept, infliximab, leflunomide, methotrexate)
  Sanofi (leflunomide)
  Santen (ciclosporin)
  Teva UK (leflunomide, methotrexate)
  Therakind (methotrexate)
  UCB Pharma (certolizumab pegol)
  Zentiva (leflunomide)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups British Epidermo-Epidemiology Society
  British Psoriatic Arthritis Consortium (BRITPACT)
  Centre of Evidence-based Dermatology, University of Nottingham
  Cochrane Musculoskeletal Group
  Cochrane Skin Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Orthopaedic Research UK
  Skin Treatment and Research Trust

Timeline

Key events during the development of the guidance:

Date Update
09 June 2020 Invitation to participate
13 May 2020 Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available.
08 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
20 November 2019 - 18 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance